Expert Answers to HCP Questions on CAR T-Cell Therapies in Myeloma and Management of Key Toxicities

Decera Clinical Education Oncology Podcast · Mar 12, 2021 · 11m

In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including:

Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin?

Could BCMA-directed CAR T-cell therapy replace transplant in the…